pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
908
stories
4d
Stakeholders call for flexibility in guidance aimed at reducing animal testing for cancer drugs
raps
4d
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
stat
4d
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
stat
4d
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
4d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
4d
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
endpoints
4d
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
4d
STAT+: The IRS is probing UnitedHealth, and a private equity slowdown
stat
4d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
4d
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
stat
4d
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
4d
Celcuity awaits FDA review for second factory to launch cancer drug
endpoints
4d
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
biopharma dive
4d
Merck KGaA lays off 20 staffers in latest blow to US research team
fiercebiotech
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca cans late-stage volrustomig trial after lung cancer setback
endpoints
4d
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
fiercebiotech
4d
FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
fiercebiotech
4d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
4d
‘Money has spoken’: Why Chinese biotech CEOs tell Fierce they’re unfazed about rising US tensions
fiercebiotech
4d
How AI-enabled Software as Medical Devices are Reshaping Regulatory Routes and Medicine
biospace
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
5d
Recon: FDA approves Zenbexus for multiple myeloma; NSAI seeks buyer for its MDR notified body business
raps
7d
Biogen's monoclonal antibody felzartamab wins first global approval in China
endpoints
7d
STAT+: PBMs agree to display TrumpRx drug prices
stat
7d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
7d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
7d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
7d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
← prev
page 3 of 31
next →
